Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Designs for single- or multiple-agent phase I trials.

Mark R Conaway1, Stephanie Dunbar, Shyamal D Peddada

  • 1Division of Biostatistics and Epidemiology, Department of Health Evaluation Sciences, The University of Virginia, Charlottesville, Virginia 22908, USA. mconway@virginia.edu

Biometrics
|September 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of oral bacteria composition and functional gene profiles in respiratory diseases.

BMJ open respiratory research·2026
Same author

Growth of Children With Cerebral Palsy and Health Outcomes.

Pediatrics·2026
Same author

Household environmental characteristics influence the house dust metagenome.

Environmental research·2026
Same author

Perinatal Arterial Ischemic Stroke Phase 3 Trial Protocol for Intensive Infant-Toddler Rehabilitation (I-ACQUIRE).

Stroke·2026
Same author

Protein phosphatase 2A subunit B55 alpha is required for angiotensin type 2 receptor elicited natriuresis.

American journal of physiology. Renal physiology·2025
Same author

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.

Clinical pharmacology and therapeutics·2025
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

This study introduces a new design for phase I oncology trials with multiple cytotoxic agents. It addresses challenges in defining dose-toxicity relationships when monotonicity is not assumed, improving maximally tolerated dose identification.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Phase I oncology trials typically use single cytotoxic agents and assume monotonic dose-toxicity.
  • Investigating combinations of cytotoxic agents requires methods beyond simple monotonic assumptions.
  • Defining dose-toxicity relationships becomes complex with multiple agents.

Purpose of the Study:

  • To present a novel design for phase I trials involving multiple cytotoxic agents.
  • To address situations where dose-toxicity probabilities follow a partial order.
  • To evaluate the performance of the new design against existing methods.

Main Methods:

  • The proposed design accommodates toxicity probabilities that follow a partial order.
  • This means the exact ordering of toxicity is not known for all treatment pairs initially.

Related Experiment Videos

  • The design's properties were investigated for specific partial orders and compared to simple order methods.

    • Main Results:

    • The new design offers a framework for dose-finding in complex multi-agent scenarios.
    • Comparison with existing methods for simple orders was conducted.
    • Properties of the design were analyzed for two distinct partial orders.

    Conclusions:

    • The presented design provides a flexible approach for phase I multi-agent oncology trials.
    • It allows for dose escalation when toxicity relationships are not strictly monotonic.
    • This advances the methodology for identifying maximally tolerated doses in combination therapies.